A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

Ruben T. H. M. Larue, Lien Van de Voorde*, Maaike Berbee, Wouter J. C. van Elmpt, Ludwig J. Dubois, Kranthi M. Panth, Sarah G. J. A. Peeters, Ann Claessens, Wendy M. J. Schreurs, Marius Nap, Fabienne A. R. M. Warmerdam, Frans L. G. Erdkamp, Meindert N. Sosef, Philippe Lambin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number644
JournalBMC Cancer
Publication statusPublished - 17 Aug 2016


  • Oesophageal cancer
  • Neoadjuvant chemoradiotherapy
  • Evofosfamide
  • Oesophagectomy
  • Dose limiting toxicity
  • Hypoxia imaging
  • Window-of-opportunity trial

Cite this